Paris, France, April 24, 2012 – Nanobiotix, a company developing novel cancer nanotherapeutics, today announced it has appointed Dr. Bernd Muehlenweg, currently “Head of Business Development” as a member of the Executive Board in support of the future growth of Nanobiotix.
“Bernd’s expertise and experience with business development over the past twelve years and his involvement in the biotech and pharma industry added a lot of value to Nanobiotix during his tenure with us,” said Dr. Laurent Levy, CEO and co-founder of Nanobiotix. “I very much look forward to working with him as we continue to further develop and validate our NanoXray product pipeline and to grow Nanobiotix.”
Bernd Mühlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director Business Development of oncology company WILEX AG (Munich, Germany), where he played a key role in the negotiation and execution of several license and commercialization agreements with pharma companies and in alliance management. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Pharma Licensing Club France.
ABOUT NANOBIOTIX – www.nanobiotix.com
Nanobiotix is a Paris, France, based nanomedicine company dedicated to the development of new cancer treatments. The company combines the advantages of nanotechnology and biotechnology. Nanobiotix is a spin-off of the State University of New York at Buffalo and was incorporated in 2003. It is funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CM-CIC Capital Innovation and MasseranGestion – CGE). With the development of several new compounds, Nanobiotix's objective is to enhance its leading position in the nanomedicine field.